Adamas Pharmaceuticals, Inc. (ADMS): Price and Financial Metrics

Adamas Pharmaceuticals, Inc. (ADMS): $8.22

0.06 (+0.74%)

POWR Rating

Component Grades








Add ADMS to Watchlist
Sign Up

ADMS Price/Volume Stats

Current price $8.22 52-week high $9.15
Prev. close $8.16 52-week low $4.02
Day low $8.18 Volume 3,151,400
Day high $8.25 Avg. volume 692,487
50-day MA $6.93 Dividend yield N/A
200-day MA $5.54 Market Cap 376.37M

ADMS Stock Price Chart Interactive Chart >

Adamas Pharmaceuticals, Inc. (ADMS) Company Bio

Adamas Pharmaceuticals is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company was founded in 2000 and is based in Emeryville, California.

ADMS Latest News Stream

Event/Time News Detail
Loading, please wait...

ADMS Latest Social Stream

Loading social stream, please wait...

View Full ADMS Social Stream

Latest ADMS News From Around the Web

Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” said Jack Khattar, President and CEO of Supern

Yahoo | November 24, 2021

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Com

Yahoo | November 23, 2021

STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

NEW YORK, NY / ACCESSWIRE / November 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc.

Yahoo | November 13, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | November 9, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | November 9, 2021

Read More 'ADMS' Stories Here

ADMS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 48.64%
5-year 74.89%
2023 N/A
2022 N/A
2021 0.00%
2020 14.25%
2019 -55.62%

Continue Researching ADMS

Here are a few links from around the web to help you further your research on Adamas Pharmaceuticals Inc's stock as an investment opportunity:

Adamas Pharmaceuticals Inc (ADMS) Stock Price | Nasdaq
Adamas Pharmaceuticals Inc (ADMS) Stock Quote, History and News - Yahoo Finance
Adamas Pharmaceuticals Inc (ADMS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!